Diphenoxylate
Active ingredient: Diphenoxylate Hydrochloride
In short: Diphenoxylate hydrochloride and atropine sulfate tablets are effective as adjunctive therapy in the management of diarrhea
What is Diphenoxylate used for?
Diphenoxylate hydrochloride and atropine sulfate tablets are
effective as adjunctive therapy in the management of diarrhea
âš Boxed warning (FDA's strongest warning)
THIS IS NOT AN INNOCUOUS DRUG AND
DOSAGE RECOMMENDATIONS SHOULD BE STRICTLY ADHERED TO, ESPECIALLY IN CHILDREN.
DIPHENOXYLATE HCl AND ATROPINE SULFATE IS NOT RECOMMENDED FOR CHILDREN UNDER 2
YEARS OF AGE. OVERDOSAGE MAY RESULT IN SEVERE RESPIRATORY DEPRESSION AND COMA,
POSSIBLY LEADING TO PERMANENT BRAIN DAMAGE OR DEATH . THEREFORE, KEEP THIS MEDICATION OUT OF THE REACH
OF CHILDREN.
THE USE OF DIPHENOXYLATE HCl AND ATROPINE SULFATE SHOULD BE ACCOMPANIED BY
APPROPRIATE FLUID AND ELECTROLYTE THERAPY, WHEN INDICATED. IF SEVERE DEHYDRATION
OR ELECTROLYTE IMBALANCE IS PRESENT, THIS PRODUCT SHOULD BE WITHHELD UNTIL
APPROPRIATE CORRECTIVE THERAPY HAS BEEN INITIATED. DRUG-INDUCED INHIBITION OF
PERISTALSIS MAY RESULT IN FLUID RETENTION IN THE INTESTINE, WHICH MAY FURTHER
AGGRAVATE DEHYDRATION AND ELECTROLYTE IMBALANCE. DIPHENOXYLATE HCl AND ATROPINE
SULFATE SHOULD BE USED WITH SPECIAL CAUTION IN YOUNG CHILDREN BECAUSE THIS AGE
GROUP MAY BE PREDISPOSED TO DELAYED DIPHENOXYLATE TOXICITY AND BECAUSE OF THE
GREATER VARIABILITY OF RESPONSE IN THIS AGE GROUP.
Antiperistaltic agents may prolong and/or worsen diarrhea associated with
organisms that penetrate the intestinal mucosa (toxigenic E.
Coli, Salmonella, Shigella), and pseudomembranous enterocolitis
associated with broad-spectrum antibiotics. Antipersistaltic agents should not
be used in these conditions.
In some patients with acute ulcerative colitis, agents that inhibit
intestinal motility or prolong intestinal transit time have been reported to
induce toxic megacolon. …
Diphenoxylate dosage
DO NOT EXCEED RECOMMENDED DOSAGE.
The recommended initial dosage is two tablets four times daily
(20 mg per day). Most patients will require this dosage until initial control
has been achieved, after which the dosage may be reduced to meet individual
requirements. Control may often be maintained with as little as 5 mg (two
tablets) daily.
Clinical improvement of acute diarrhea is usually observed within 48 hours.
If clinical improvement of chronic diarrhea after treatment with a maximum daily
dose of 20 mg of diphenoxylate hydrochloride is not observed within 10 days,
symptoms are unlikely to be controlled by further administration.
Diphenoxylate HCl and atropine sulfate is not
recommended in children under 2 years of age and should be used with special
caution in young children . The nutritional status
and degree of dehydration must be considered. In children under 13 years of age,
use oral solution. Do not use tablets for this age group.
KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
How to take Diphenoxylate — instructions & advice from the label
INFORM THE PATIENT (PARENT OR GUARDIAN) NOT TO EXCEED THE
RECOMMENDED DOSAGE AND TO KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN AND IN
A CHILD-RESISTANT CONTAINER. INFORM THE PATIENT OF THE CONSEQUENCES OF
OVERDOSAGE, INCLUDING SEVERE RESPIRATORY DEPRESSION AND COMA, POSSIBLY LEADING
TO PERMANENT BRAIN DAMAGE OR DEATH. Diphenoxylate HCl and atropine sulfate may
produce drowsiness or dizziness. The patient should be cautioned regarding
activities requiring mental alertness, such as driving or operating dangerous
machinery. Potentiation of the action of alcohol, barbiturates, and
tranquilizers with concomitant use of this product should be explained to the
patient. The physician should also provide the patient with other information in
this labeling, as appropriate.
Known drug interactions include barbiturates, tranquilizers, and
alcohol. Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors
.
In studies with male rats, diphenoxylate hydrochloride was found to inhibit
the hepatic microsomal enzyme system at a dose of 2 mg/kg/day. …
Warnings & precautions
Do not take this medicine if: Diphenoxylate HCl and atropine sulfate tablets are
contraindicated in patients with:
known hypersensitivity to diphenoxylate or atropine.
obstructive jaundice.
diarrhea associated with pseudomembranous enterocolitis or
enterotoxin-producing bacteria
Diphenoxylate side effects
At therapeutic doses, the following have been reported; they are
listed in decreasing order of severity, but not of frequency:
Numbness of extremities, euphoria, depression, malaise/lethargy,
confusion, sedation/drowsiness, dizziness, restlessness, headache
Anaphylaxis, angioneurotic edema, urticaria, swelling of the
gums, pruritus
Toxic megacolon, paralytic ileus, pancreatitis, vomiting, nausea,
anorexia, abdominal discomfort The following atropine sulfate effects are listed
in decreasing order of severity, but not of frequency: hyperthermia,
tachycardia, urinary retention, flushing, dryness of the skin and mucous
membranes. These effects may occur, especially in children.
THIS MEDICATION SHOULD BE KEPT IN A CHILD-RESISTANT CONTAINER AND OUT OF THE
REACH OF CHILDREN SINCE AN OVERDOSAGE MAY RESULT IN SEVERE RESPIRATORY
DEPRESSION AND COMA, POSSIBLY LEADING TO PERMANENT BRAIN DAMAGE OR DEATH.
About this medicine
Each tablet, for oral administration, contains:
Diphenoxylate Hydrochloride USP . . . . . . . . . . . 2.5 mg
Atropine Sulfate USP . . . . . . . . . . . . . . . . . . . . . 0.025 mg
In addition, each tablet, contains the following inactive ingredients:
confectioner’s sugar, corn starch, lactose monohydrate, magnesium stearate and
sodium starch glycolate.
Diphenoxylate hydrochloride, an antidiarrheal, is ethyl
1-(3-cyano-3,3-diphenylpropyl)-4-phenylisonipecotate monohydrochloride and has
the following structural formula:
C30H32N2O2•HCl M.W. 489.06
Atropine sulfate, an anticholinergic, is Benzeneacetic
acid,-(hydroxymethyl)-8-methyl-8-azabicyclol [3.2.1] oct-3-yl ester, endo-±, sulfate(2:1) (salt), monohydrate and has the
following structural formula:
C17H23NO3)2•H2SO4•H20 M.W. 694.85
A subtherapeutic amount of atropine sulfate is present to discourage
deliberate overdosage.
How it works: Diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 542b6ceb-7ad4-4d0d-b604-79bd1f567d79. Read the full official label on DailyMed.